Patents Assigned to The Medical College of Hampton Road
  • Method of inhibiting fertilization
    Patent number: 5516769
    Abstract: Fertilization of an oocyte is inhibited by administering a fertilizing inhibitory amount of an antiprogestin to an ovulatory mammal in an amount which is insufficient to prevent ovulation but sufficient to inhibit fertilization, while the regularity of the menstrual cycle is sustained.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: May 14, 1996
    Assignee: The Medical College of Hampton Roads
    Inventor: Gary D. Hodgen
  • Hormone replacement therapy
    Patent number: 5468736
    Abstract: A method of hormone replacement therapy involves the administration of estrogen together with an amount of antiprogestin which inhibits estrogen-induced endometrial proliferation in a woman.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: November 21, 1995
    Assignee: The Medical College of Hampton Road
    Inventor: Gary D. Hodgen
  • Isolated nucleotide sequences encoding an: antigen binding site of monoclonal antibody PD41; and antigen associated with prostate adenocarcinomas
    Patent number: 5314996
    Abstract: Monoclonal antibodies that bind specifically to prostate carcinoma and do not bind substantially to normal prostate or benign prostatic hyperplasia, as well as hybridoma cell lines producing the monoclonal antibodies are disclosed. In one embodiment, a monoclonal antibody designated MAb PD41 is disclosed. A new antigen designated prostate mucin antigen is disclosed in isolated, substantially pure form. In addition, methods for using the hybridoma cell lines, the monoclonal antibody and/or the antigen for diagnosis, prophylaxis and/or treatment of prostate carcinoma are disclosed.
    Type: Grant
    Filed: July 13, 1993
    Date of Patent: May 24, 1994
    Assignee: Eastern Virginia Medical School of Medical College of Hampton Roads
    Inventor: George L. Wright, Jr.
  • Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
    Patent number: 5227471
    Abstract: Monoclonal antibodies that bind specifically to prostate carcinoma and do not bind substantially to normal prostate or benign prostatic hyperplasia, as well as hybridoma cell lines producing the monoclonal antibodies are disclosed. In one embodiment, a monoclonal antibody designated MAb PD41 is disclosed. A new antigen designated prostate mucin antigen is disclosed in isolated, substantially pure form. In addition, methods for using the hybridoma cell lines, the monoclonal antibody and/or the antigen for diagnosis, prophylaxis and/or treatment of prostate carcinoma are disclosed.
    Type: Grant
    Filed: January 30, 1992
    Date of Patent: July 13, 1993
    Assignee: Eastern Virginia Medical School of the Medical College of Hampton Roads
    Inventor: George L. Wright, Jr.
  • Method and kit for contraception with GnRH-antagonist
    Patent number: 5116818
    Abstract: A method of providing contraception for and regulation of the menstrual cycle of a gonadal female mammal by a) administering thereto about once a week throughout her menstrual cycle an amount of a GnRH-antagonist effective to block folliculogenesis and thereby achieve a contraceptive state but less than the amount thereof required to block hormonogenesis; and b) inducing menses by administering during the last half of that cycle an amount of a progestin effective to produce a secretory endometrium and then terminating the progestin administration.
    Type: Grant
    Filed: August 9, 1990
    Date of Patent: May 26, 1992
    Assignee: Medical College of Hampton Roads
    Inventors: Gary D. Hodgen, Daniel Kenigsberg